Relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.
Impact
The bill is set to take effect on September 1, 2025, applying to health benefit plans that are delivered, issued for delivery, or renewed on or after January 1, 2026. Existing health plans prior to this date will continue to operate under current regulations. The intended impact is to align insurance practices with the needs of patients, allowing them greater ease in securing necessary medications without facing repeated authorization requests.
Summary
Senate Bill 1812 aims to amend the Texas Insurance Code regarding prior authorization for prescription drug benefits specifically for the treatment of neurodegenerative diseases. The legislation proposes to limit health benefit plan issuers from requiring more than one prior authorization annually for prescriptions related to these diseases, which includes conditions such as autoimmune diseases and hemophilia. This change is designed to facilitate easier access to necessary medications for patients suffering from these conditions and to reduce bureaucratic hurdles that can delay treatment.
Contention
While the provision aims to streamline the process for obtaining prescription medications for these vulnerable patient populations, there could be concerns regarding how this affects insurance companies and their ability to manage costs and risks associated with high-cost prescriptions. Stakeholders may debate whether these changes would lead to increased insurance premiums or whether they could indeed result in savings by promoting earlier and more consistent treatment of neurodegenerative diseases. The balance between protecting the interests of patients and managing the financial aspects for insurance providers may become a point of contention.
Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.